Biopharma | May 20, 2026
IGI’s new drug candidate ISB 2301 to target solid tumors
The company intends to file an IND submission by the end of this year and begin clinical studies in 2027
The company intends to file an IND submission by the end of this year and begin clinical studies in 2027
Funding to accelerate development of integrated DNA platform supporting vaccines, gene therapies and advanced biologics
This positions its platform as a rapidly evolving engine for next-generation genetic medicine
The global diagnostics supplier said the multi-phase expansion aims to deliver more than 60 commercially available recombinant antigen products by 2030
Backed by Semaglutide launches, the company reported 47% quarter-on-quarter revenue growth in Q4 FY26, with EBITDA expanding more than fivefold
Shilpa will deliver end-to-end services including CMC development, process scale-up, GMP clinical supply, and commercial manufacturing support
The company’s shares of confidence were underlined by an upgraded 2026 outlook, with Merck now expecting annual net sales of up to €21.4 billion and EBITDA pre of as much as €6.1 billion
High-resolution analytical platforms from Agilent Technologies will be made available through C-CAMP’s shared infrastructure model under expanded collaboration
The two companies will establish a joint Center of Excellence (CoE) in Bengaluru
IIT Kanpur team has developed computational framework to map how cell signals influence gene activity across tissues
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
